An interventional study of No investigational study intervention in Acute Kidney Injury, Renal Insufficiency, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Bayer · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Acute Kidney Injury with a site in Germany — 21 open to participants now, 24 under way, 1 of them phase 3. Acute Kidney Injury · Germany.
Among the 109 studies in Acute Kidney Injury with a site in Germany, this one is the 51st largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 with no phase, and was the 101st registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →21 of the 109 studies in Acute Kidney Injury with a site in Germany are open now. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18+
Universität Münster · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 11 more countries
Ages 18–80
Fresenius Medical Care Deutschland GmbH · Sites in Germany, Czechia
Ages up to 18
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 7 · Phase 4 4
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 112 across the 62 interventional studies, 120 across the 47 observational. Of the 67 that completed or were terminated, 10 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 109 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 2 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
9 of the studies in Acute Kidney Injury with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06615102Phase 3Universität MünsterReducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II | 2027-01 |
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT06180551Universität des SaarlandesHomburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT06772025BayerA Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 109 studies in Acute Kidney Injury with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to investigate how reliable a test assessing the renal functional reserve (RFR) and the maximum glomerular filtration rate (maxGFR) are. MaxGFR and RFR assessments are repeated twice at 1-month intervals. If precise, this test may improve the measure of kidney function and be useful in future studies for people with chronic kidney problems.
To do this, the researchers will collect and analyze information about kidney function from up to 50 adults, including healthy people and people with stable kidney problems. Each person will come to the study center for a screening visit and then three study days, each about a month apart. On each study day, participants will have blood and urine samples taken before and after drinking a protein shake. The tests will measure things like creatinine, cystatin C, and other markers in the blood and urine to see how the kidneys are working. The study will also record basic health information, weight, blood pressure, and any medicines being taken.
The study will last about 2 to 2.5 months for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: No investigational study intervention
The study does not involve the administration of any study intervention, investigational medicinal product, or device. Participants will undergo blood collection and urine sampling both before and after consuming a high-protein meal.
Maximun kidneyfunction determined by measurement of creatinine clearance (mGFRCR)
Time frame: Day 1, 28 and 56
Renal functional reserve by measurement of creatinine clearance (mGFRCR)
Time frame: Day 1, 28 and 56
Maximum kidney function and renal functional reserve derived from serum creatinine-based eGFR (eGFRSCR)
Time frame: Day 1, 28 and 56
Maximum kidney function and renal functional reserve derived from serum cystatin C-based eGFR (eGFRCYS)
Time frame: Day 1, 28 and 56
Maximum kidney function and renal functional reserve derived from serum creatinine-based and serum cystatin C-based eGFR (eGFRSCR-CYS)
Time frame: Day 1, 28 and 56
Maximum creatinine clearance and renal functional reserve derived from plasma PENK-based eGFR (eGFRPENK)
Time frame: Day 1, 28 and 56
Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Sep 2026, 8 months.
Of 269 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 8 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Feb 2027 → Sep 2026 and completion Feb 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.